These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Aslam A; Jahnke N; Remmington T; Southern KW Paediatr Respir Rev; 2017 Sep; 24():32-34. PubMed ID: 28566196 [No Abstract] [Full Text] [Related]
26. Homozygosity for L997F in a child with normal clinical and chloride secretory phenotype provides evidence that this cystic fibrosis transmembrane conductance regulator mutation does not cause cystic fibrosis. Derichs N; Schuster A; Grund I; Ernsting A; Stolpe C; Körtge-Jung S; Gallati S; Stuhrmann M; Kozlowski P; Ballmann M Clin Genet; 2005 Jun; 67(6):529-31. PubMed ID: 15857421 [No Abstract] [Full Text] [Related]
27. Gentamicin in pharmacogenetic approach to treatment of cystic fibrosis. Hamilton JW Lancet; 2001 Dec; 358(9298):2014-6. PubMed ID: 11755605 [No Abstract] [Full Text] [Related]
28. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
29. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis. Birault V; Solari R; Hanrahan J; Thomas DY Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435 [TBL] [Abstract][Full Text] [Related]